Evidence map›Paper›PMID 33651649›Full record

ArticleCell cycle (Georgetown, Tex.)

LncRNA NBR2 aggravates hepatoblastoma cell malignancy and promotes cell proliferation under glucose starvation through the miR-22/TCF7 axis.

Chengguang Zhu, Xiangling He, Keke Chen, Zhijun Huang, Anqi Yao, Xin Tian, Yalan You, Minhui Zeng

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chengguang ZhuDepartment of Pediatric Hematology and Oncology, Children's Medical Center of Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Xiangling HeDepartment of Pediatric Hematology and Oncology, Children's Medical Center of Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Keke ChenDepartment of Pediatric Hematology and Oncology, Children's Medical Center of Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Zhijun HuangDepartment of Pediatric Hematology and Oncology, Children's Medical Center of Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Anqi YaoDepartment of Pediatric Hematology and Oncology, Children's Medical Center of Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Xin TianDepartment of Pediatric Hematology and Oncology, Children's Medical Center of Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Yalan YouDepartment of Pediatric Hematology and Oncology, Children's Medical Center of Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Minhui ZengDepartment of Pediatric Hematology and Oncology, Children's Medical Center of Hunan Provincial People's Hospital (The First-Affiliated Hospital of Hunan Normal University), Changsha, China.
Hunan Normal University · CNHunan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatoblastoma (HB) is the most commonly seen pediatric liver malignancy. With frequent mutations in CTNNB1 gene that encodes β-catenin, hepatoblastoma has been considered as a Wnt/β-catenin-activated malignant tumor. Altered glucose metabolism upon nutrient deprivation (glucose starvation) might also be a critical event in hepatoblastoma carcinogenesis. The present study provides a lncRNA NBR2/miR-22/TCF7 axis modulating proliferation, invasion, migration, and apoptosis of hepatoblastoma cells upon glucose starvation through Wnt and downstream TCF7 signaling pathways. The expression of NBR2 is significantly increased within hepatoblastoma tissue samples; moreover, under incubation with 0 mM glucose (glucose starvation), NBR2 expression is significantly upregulated. NBR2 silencing not only inhibited hepatoblastoma cell viability, invasion, and migration under normal culture condition but also promoted the cell apoptosis under glucose starvation. NBR2 silencing in hepatoblastoma cells also decreased TCF7 mRNA expression and TCF7 protein levels, as well as the protein levels of the cell cycle, glucose entrapment, and EMT markers. miR-22 is directly bound to both NBR2 and TCF7; lncRNA NBR2 counteracted miR-22-mediated repression on TCF7 via acting as a ceRNA. The effects of NBR2 silencing on TCF7 expression, hepatoblastoma cell phenotype, and cell cycle, glucose entrapment, and EMT markers were all significantly reversed by miR-22 inhibition. In conclusion, lncRNA NBR2 aggravates hepatoblastoma cell malignancy through competing with TCF7 for miR-22 binding, therefore counteracting miR-22-mediated repression on TCF7. LncRNA NBR2 might be a promising target to inhibit hepatoblastoma cell proliferation under glucose starvation.

Indexed as

Cell ProliferationGlucoseHepatoblastomaHep G2 CellsHumansMicroRNAsProtein BindingRNA, Long NoncodingT Cell Transcription Factor 1Transcription FactorsGlucoseMicroRNAsMIRN22 microRNA, humanNBR2 lncRNA, humanRNA, Long NoncodingT Cell Transcription Factor 1TCF7 protein, humanTranscription Factorsglucose starvationHepatoblastomalncRNA NBR2miR-22TCF7

Identifiers

PMID33651649
PMCPMC8018347
OpenAlexW3135823084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.